Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2022; 10(18): 6091-6104
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Ruo-Nan Wang, Department of Endocrinology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, Hubei Province, China
Author contributions: Yang HH and Zhou XC contributed to study design; Yang HH, Huang Y, and Wang RN contributed to the literature search; Yang HH, Huang Y, and Zhou XC participated in data extraction and analysis; Yang HH and Huang Y wrote the paper.
Conflict-of-interest statement: Nothing to disclosed.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu-Chun Zhou, MD, Professor, Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. chqxchzh@163.com
Received: December 29, 2021
Peer-review started: December 29, 2021
First decision: January 25, 2022
Revised: February 14, 2022
Accepted: April 30, 2022
Article in press: April 30, 2022
Published online: June 26, 2022
Processing time: 169 Days and 12.8 Hours
Peer-review started: December 29, 2021
First decision: January 25, 2022
Revised: February 14, 2022
Accepted: April 30, 2022
Article in press: April 30, 2022
Published online: June 26, 2022
Processing time: 169 Days and 12.8 Hours
Core Tip
Core Tip: Differences in immunogenicity and route of administration among adalimumab (ADA) and infliximab (IFX) allow for potential variability in therapeutic properties and efficacy. However, clear recommendations have been limited due to a lack of head-to-head comparison. We conducted a meta-analysis to synthesize current results and compared the efficacy and safety of ADA and IFX. The results showed that both have similar clinical benefits for anti-tumor necrosis factor-α naïve or non-naïve Crohn’s disease patients. Overall adverse events rate is higher in patients in the IFX group. ADA and IFX can be selected based on a possible history of adverse events and patient compliance.